MyBody-X angle on Abnehmspritze Kinder

The question about 'weight loss shots' (GLP-1 agonists like semaglutide) for children is outside MyBody-X's direct product and knowledge scope. The provided contexts cover DNA tests for gluten intolerance, a nutrient vital check, polygenic scores for diet, and microbiome tests – but not pharmacological obesity therapy. GLP-1 medications are approved for children only in specific, medically supervised cases (e.g., severe obesity from age 12) and have strict safety requirements. A genetic or microbiome test could theoretically explore factors like insulin resistance or gut flora, but evidence for predicting individual response to these drugs is weak and not supported by the given sources. MyBody-X products are designed as supplementary health checks, not diagnostics or treatment decisions. For children with obesity, medical evaluation (pediatrician, endocrinology) is essential. Evidence for GLP-1 use in adolescents is 'human-moderate' (from approval trials) but absent from the provided contexts. Therefore: no direct statement possible; caution against marketing claims.